Arvee Laboratories (India) share news, announcements and annual reports
NSE: ARVEEChemicals & PetrochemicalsSmall Cap
Arvee Laboratories (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2018 · Issue price ₹61
Last close ₹210.15up ₹3.44 (1.66%)
Share price at the NSE close on 2 Nov 2026. Previous close ₹206.71.
2 Nov: open ₹217.04, high ₹217.04, low ₹209.00
52-week range of traded prices to 2 Nov 2026
₹129.11Low, 30 Mar 2026₹290.78High, 19 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 2 Nov 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹232 Cr2,476th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.16
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.85
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,46356.7% delivered
Arvee Laboratories (India) share news and announcements
259 announcements, routine notices left out, newest first. Page 5 of 6.
Apr 2020
Mar 2020
Jan 2020
Dec 2019
2 Dec · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Nov 2019
15 Nov · Results
14 Nov · Board meeting
12 Nov · Board meeting
Oct 2019
Sep 2019
26 Sep · Management
Aug 2019
Jul 2019
Jun 2019
26 Jun · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 24-Jun-2019, regarding cessation of Mr SAUMIL BHARATBHAI CHOKSHI as Director of the company w.e.f. Jun 24, 2019. On basis of above the Company is required to clarify following: 1. In case of Independent Director, provide a confirmation that there is no other material reason for resignation 2. Reason for resignation. The response of the Company is awaited.13 Jun · Related Party Transactions
May 2019
27 May · Results
18 May · Board meeting
Apr 2019
Mar 2019
29 Mar · Board meeting
Feb 2019
Jan 2019
Nov 2018
21 Nov · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.13 Nov · Results
13 Nov · Results
Oct 2018
Aug 2018
18 Aug · Updates
Jul 2018
May 2018
31 May · Results
30 May · Statement on Impact of Audit Qualifications
30 May · Results
24 May · Management
22 May · Board meeting
11 May · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 11-May-2018, regarding " Arvee Laboratories (India) Limited has informed the Exchange regarding Appointment of Mr Saurin A Gandhi as Chief Financial Officer of the company w.e.f. May 10, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
Apr 2018
Mar 2018